ArticleFrontiers in immunology2026
Source-renewing ectopic ApoB-TRL lipolysis in non-resolving ARDS: a testable spatial hypothesis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) may remain regionally permeable and poorly reparative after the initiating insult has weakened. We propose that, in a biologically enriched subset of non-resolving ARDS, repeated entry of circulating apolipoprotein B-containing triglyceride-rich lipoproteins (ApoB-TRLs) into an injured perivascular or interstitial compartment provides a renewable substrate for local injury. Catalytically active lipoprotein lipase (LPL) converts particle triglyceride (TG) to free fatty acids (FFAs). When FFA generation exceeds albumin buffering, cellular disposal, and lymphatic removal, redox and lipid-mediator signaling induces a focused cytokine program and recruits neutrophils. Oxidants, proteases, and neutrophil extracellular trap (NET)-fibrin complexes then injure the glycocalyx, junctions, matrix, and epithelium, permitting entry of the next particle cohort. Renewed source-resolved input, rather than lipid abundance alone, distinguishes a self-maintaining loop from a finite amplifier. Effective LPL activity, a macrophage brake, regional hypoxia, and slow structural locks modify circuit phase and reversibility but do not define loop closure. Spatial progression is predicted to be signal-first: mobile inflammatory or coagulation relays prime a remote endothelial gate, while fresh substrate is supplied by the recipient microcirculation. The decisive prediction is ordered recurrence in the same microdomain: source-resolved entry and conversion precede inflammatory execution and barrier loss, and interrupting a verified downstream executor after matching the first input prevents a second particle input. Failure of this sequence would narrow or reject the hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.